Abstract 915P
Background
To compare survival outcomes and toxic effects among patients with newly diagnosed nonmetastatic nasopharyngeal carcinoma (NPC) when treated with Intensity modulated radiotherapy (IMRT) versus IMRT + carbon-ion radiotherapy (CIRT).
Methods
We performed a retrospective propensity score matching analysis (1:1) of patients treated with IMRT and IMRT + CIRT. Survival was estimated using the Kaplan–Meier method. Multivariate Cox proportional hazards regression analysis was used to identify the independent predictors of survival. We examined the association between risk factors and adverse events (AEs) using Chi-squared tests. AEs analyses were performed using a Cox model and logistic regression.
Results
109 patients who received IMRT + CIRT were included and the median follow-up time was 20.6 months (range: 4.6-82 months). There were no statistically significant differences in locoregional failure–free survival, distant metastasis–free survival, disease-free survival, or overall survival between the two groups, but potentially better in IMRT + CIRT group (P > 0.05, respectively). Nodal boost was the only significant factor associated with LRFS and DFS on multivariable analysis. 37 patients (34.0%) developed grade 3 acute OMs and no grade 4 acute OMs were observed in IMRT + CIRT group. All patients in IMRT + CIRT group developed grade 1 dermatitis. IMRT +CIRT treatment was associated with a significant trend of lower grades of OM and dermatitis (P < 0.05, respectively). Any severe (ie, grade 3) chronic AEs, such as xerostomia, skin fibrosis, temporal lobe necrosis, osteoradionecrosis, or radiation-induced optic neuropathy, was not observed.
Conclusions
IMRT + CIRT for primary nonmetastatic NPC was associated with significantly reduced oral mucositis and dermatitis compared with full course of IMRT, with excellent survival outcomes. Patients with persistent disease after primary treatment and treated with nodal boost had a worse outcome. More accurate assessments of IMRT + CIRT to primary nonmetastatic NPC patients will be imperative.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The study was funded by the Clinical research on health industry of Shanghai Health Commission (grant numbers: 20214Y0025) The study was funded by the Clinical research of Shanghai Pudong District Health Commission (grant numbers: PW2022A-41).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
878P - INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype
Presenter: Simon Laban
Session: Poster session 12
880P - ctHPV16-DNA in Liquid Biopsy: A promising biomarker to monitor disease status in patients with HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Nora Würdemann
Session: Poster session 12
881P - SOTO study: Prospective study to correlate the treatment sensitivity of patient-derived organoids (PDOs) with treatment outcomes in head and neck cancer patients
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
882P - Claudin-1 (CLDN1) expression in head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Stefano Cavalieri
Session: Poster session 12
884P - Prognostic value and immune characteristics of LGALS1 in head and neck squamous cell carcinoma
Presenter: Yanfei Min
Session: Poster session 12
885P - Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in nasopharyngeal carcinoma
Presenter: Dingyi Wang
Session: Poster session 12
887P - Antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival: Exploratory analyses from a phase I in cisplatin-ineligible locally advanced HNSCC patients
Presenter: Christophe Le Tourneau
Session: Poster session 12
888P - Phase I study of olaparib combined with loco-regional radiotherapy in patients with head and neck squamous cell carcinoma
Presenter: Marcel Verheij
Session: Poster session 12